Browse Articles
Discover research articles across all indexed journals
Effect of repeated sprint exercise on immunological responses in adult and adolescent athletes at different stages of biological maturation: a-quasi-experimental-trial
Experimental study on mechanical response characteristics of gassy sand under constant shear stress paths
Factors associated with unfavourable treatment outcomes among patients with Multidrug-resistant Tuberculosis receiving outpatients care
Compensatory cerebellar activation during fluid intelligence processing following mild traumatic brain injury
Psychometric validation and correlates of the personal safety perception scale (PSPS-26) as a multidimensional measure of perceived safety
Multiomics profiling reveals systemic biological responses to severe subacute exposure to heated tobacco products in rats
Effects of tobacco intercropping on the Spatial relationship between natural enemies and pests and economic efficiency
Cobalamin and iron deficiency still presents a challenge in hereditary hemorrhagic telangiectasia
Abstract Hereditary hemorrhagic telangiectasia (HHT) leads to fragile blood vessels, causing frequent bleeding and anemia. Treatment mainly addresses iron levels and substitution. Although cobalamin (vitamin B12) is routinely tested in chronic anemia, its role in HHT has not been studied until now. This study examined its prevalence and related symptoms in HHT patients. Data from HHT patients treated between July 2019 and November 2022 were analyzed. Patients with cobalamin levels under 400 pg/ml underwent further testing and questioning. Among 155 patients, 42% were anemic, and 45% had cobalamin levels below 400 pg/ml. However, only 7 patients had a confirmed deficiency. Still, many reported symptoms commonly but not specifically linked to cobalamin deficiency, even with low-normal levels. Gastrointestinal lesions were significantly associated with these low-normal values (p = 0.027). Furthermore, 59% of patients had iron deficiency, and 67% were not receiving iron therapy at the time of their visit. This study is the first to show that true cobalamin deficiency is not more common in HHT than in the general population, though low-normal levels are frequent. In case of unexplained symptoms, evaluating cobalamin levels should be taken into consideration.
On the sensing performance improvement in SPR biosensor using ZnO and TMDCs architecture for cancer detection
Enhanced Q learning and deep reinforcement learning for unmanned combat intelligence planning in adversarial environments
Internet of things enabled deep learning monitoring system for realtime performance metrics and athlete feedback in college sports
Caffeine-augmented exercise as a pretreatment for locomotor and balance impairments induced by REM sleep deprivation in rats
Virulence and genome analysis of baculovirus isolates from different Lymantria dispar populations
Science populism impacts perceptions of credibility across scientific professions
A novel passive shimming optimization method of MRI magnet based on a PSA-SQP hybrid algorithm
Firefly algorithm with multiple learning ability based on gender difference
Comparable efficacy of generic and original alginate for symptom control in PPI-refractory GERD
Abstract Gastroesophageal reflux disease (GERD) is a prevalent global condition, affecting 18.1–27.8% of North Americans and 6.3–18.3% of the Thai population. While proton pump inhibitors (PPIs) are the first-line treatment, only about one-third of patients achieve adequate symptom control. Alginate-based medications in combination with PPIs have shown promise, but the comparative effectiveness of generic versus original alginates remains unexplored. To compare the effectiveness of generic alginate (ONE GERD) versus original alginate (Gaviscon Dual Action Suspension) in combination with PPIs for treating GERD symptoms in patients who failed standard PPI therapy.This multicenter prospective randomized controlled non-inferiority trial included 48 patients who failed standard-dose PPI treatment. Patients were randomized to receive either generic or original alginate four times daily for 28 days. Treatment response was evaluated using the Reflux Disease Questionnaire (RDQ) at days 7 and 28. At day 7, both groups showed identical response rates of 45.83%. By day 28, response rates increased to 54.17% for generic alginate and 70.83% for original alginate (p = 0.23). Total RDQ scores and symptom-free rates showed no significant differences between groups at both time points. Adverse event rates were comparable (16.67% vs. 8.33%, p = 0.66). Analysis of specific symptoms (heartburn, chest pain, and regurgitation) revealed similar improvements in both groups throughout the study period. This study provides evidence supporting the therapeutic equivalence of the generic alginate (ONE GERD) to the original formulation (Gaviscon Dual Action Suspension) in treating symptoms for patients with GERD who have failed PPI therapy. Crucially, the comparable efficacy and safety, coupled with the inherent lower cost of generic medications, suggest significant economic benefits and the potential for wider patient access to effective GERD management. This makes generic alginate a viable and attractive alternative in clinical practice, particularly in resource-limited settings or for patients facing financial constraints, thereby contributing to more equitable healthcare solutions without compromising therapeutic outcomes.